Effectiveness of Wellbeing Intervention for Chronic Kidney Disease (WICKD): results of a randomised controlled trial

Author:

Dingwall Kylie M.,Sweet Michelle,Cass Alan,Hughes Jaquelyne T.,Kavanagh David,Howard Kirsten,Barzi Federica,Brown Sarah,Sajiv Cherian,Majoni Sandawana W.,Nagel Tricia

Abstract

Abstract Background End stage kidney disease (ESKD) is associated with many losses, subsequently impacting mental wellbeing. Few studies have investigated the efficacy of psychosocial interventions for people with ESKD and none exist for Indigenous people, a population in which the ESKD burden is especially high. Methods This three-arm, waitlist, single-blind randomised controlled trial examined efficacy of the Stay Strong App in improving psychological distress (Kessler distress scale; K10), depressive symptoms (adapted Patient Health Questionnaire; PHQ-9), quality of life (EuroQoL; EQ. 5D) and dialysis adherence among Indigenous Australians undergoing haemodialysis in central and northern Australia (Alice Springs and Darwin), with follow up over two 3-month periods. Effects of immediate AIMhi Stay Strong App treatment were compared with those from a contact control app (The Hep B Story) and treatment as usual (TAU). Control conditions received the Stay Strong intervention after 3 months. Results Primary analyses of the full sample (N = 156) showed statistically significant decreases in K10 and PHQ-9 scores at 3 months for the Hep B Story but not for the Stay Strong app or TAU. Restricting the sample to those with moderate to severe symptoms of distress or depression (K10 > =25 or PHQ-9 > =10) showed significant decreases in K10 and PHQ-9 scores for both Stay Strong and Hep B Story. No significant differences were observed for the EQ-5D or dialysis attendance. Conclusions Findings suggest that talking to people about their wellbeing and providing information relevant to kidney health using culturally adapted, locally relevant apps improve the wellbeing of people on dialysis. Further research is required to replicate these findings and identify active intervention components. Trial registration ACTRN12617000249358; 17/02/2017.

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Reference36 articles.

1. Australian Institute of Health and Welfare. Chronic kidney disease [Cat. no. CDK 16]. Canberra: AIHW; 2019.

2. ANZDATA Registry. 42nd report, chapter 10: end stage kidney disease in Aboriginal and Torres Strait islander Australians. Adelaide: Australia and New Zealand Dialysis and Transplant Registry; 2020.

3. Australian Institute of Health and Welfare. Profiles of Aboriginal and Torres Strait Islander people with kidney disease. Cat. no. IHW 229. Canberra: AIHW; 2020.

4. Lawton PD, Cunningham J, Hadlow N, Zhao Y, Jose MD. Chronic kidney disease in the top end of the Northern Territory of Australia, 2002-2011: a retrospective cohort study using existing laboratory data. BMC Nephrol. 2015;16(1):168. https://doi.org/10.1186/s12882-015-0166-6.

5. Devitt J, McMasters A. They don’t last long’: Aboriginal patient experience of end-stage renal disease in Central Australia. Nephrology. 1998;4(s2):S111–S7. https://doi.org/10.1111/j.1440-1797.1998.tb00485.x.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3